Log in

NASDAQ:MTEM - Molecular Templates Stock Price, Forecast & News

+0.91 (+5.84 %)
(As of 02/21/2020 08:24 AM ET)
Today's Range
Now: $16.49
50-Day Range
MA: $14.39
52-Week Range
Now: $16.49
Volume375,000 shs
Average Volume281,863 shs
Market Capitalization$609.64 million
P/E RatioN/A
Dividend YieldN/A
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MTEM



Sales & Book Value

Annual Sales$13.28 million
Book Value$2.75 per share


Net Income$-30,290,000.00
Net Margins-289.90%


Market Cap$609.64 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Shares of Molecular Templates reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) issued its earnings results on Monday, August, 12th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The biotechnology company had revenue of $5.45 million for the quarter, compared to analyst estimates of $6 million. Molecular Templates had a negative return on equity of 44.86% and a negative net margin of 289.90%. View Molecular Templates' Earnings History.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Molecular Templates.

What price target have analysts set for MTEM?

2 brokers have issued 12-month target prices for Molecular Templates' shares. Their forecasts range from $12.00 to $12.00. On average, they expect Molecular Templates' stock price to reach $12.00 in the next year. This suggests that the stock has a possible downside of 27.2%. View Analyst Price Targets for Molecular Templates.

What is the consensus analysts' recommendation for Molecular Templates?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Molecular Templates.

Has Molecular Templates been receiving favorable news coverage?

Press coverage about MTEM stock has trended somewhat positive on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Molecular Templates earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Molecular Templates.

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest in January. As of January 15th, there was short interest totalling 1,260,000 shares, an increase of 10.5% from the December 31st total of 1,140,000 shares. Based on an average daily volume of 348,800 shares, the days-to-cover ratio is currently 3.6 days. Currently, 5.7% of the company's shares are short sold. View Molecular Templates' Current Options Chain.

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Alibaba Group (BABA), SLS International (SLS) and ACADIA Pharmaceuticals (ACAD).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the folowing people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
  • Ms. Jason S Kim, Pres & COO (Age 44)
  • Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by a number of of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.08%), Perceptive Advisors LLC (6.69%), FMR LLC (1.31%), Sectoral Asset Management Inc (1.17%), Parkman Healthcare Partners LLC (0.92%) and Geode Capital Management LLC (0.79%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii and Scott D Morenstein. View Institutional Ownership Trends for Molecular Templates.

Which major investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including AXA, BVF Inc. IL, Goldman Sachs Group Inc., UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Molecular Templates.

Which major investors are buying Molecular Templates stock?

MTEM stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Parkman Healthcare Partners LLC, Monashee Investment Management LLC, Abingworth LLP, Sectoral Asset Management Inc, Man Group plc and EAM Investors LLC. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii and Scott D Morenstein. View Insider Buying and Selling for Molecular Templates.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $16.49.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $609.64 million and generates $13.28 million in revenue each year. The biotechnology company earns $-30,290,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.View Additional Information About Molecular Templates.

What is Molecular Templates' official website?

The official website for Molecular Templates is http://www.mtem.com/.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]

MarketBeat Community Rating for Molecular Templates (NASDAQ MTEM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  588
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel